🇺🇸 FDA
Patent

US 10125369

PCSK9 iRNA compositions and methods of use thereof

granted A61KA61K31/713A61K47/549

Quick answer

US patent 10125369 (PCSK9 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
85
CPC classes
A61K, A61K31/713, A61K47/549, A61P, A61P3/06